06:58:18 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Orphazyme är verksamma inom biokemi. Bolaget är specialiserade mot forskning och utveckling av ovanliga sjukdomar där det finns en brist i funktionen hos värmekokproteiner. Tekniken baseras på arimoklomol, som stimulerar produktionen av värmekokproteiner i celler som upplever en ökad grad av stress och toxicitet. Sjukdomar som ämnar behandlas med bolagets produkter innefattar Gauchers sjukdom och amyotrofisk lateral skleros (ALS). Bolaget har sitt huvudkontor i Köpenhamn.

Kalender

2021-08-31 Kvartalsrapport 2021-Q2
2021-03-26 Ordinarie utdelning ORPHA 0.00 DKK
2021-03-25 Årsstämma 2021
2021-03-02 Bokslutskommuniké 2020
2020-09-21 Extra Bolagsstämma 2020
2020-08-28 Kvartalsrapport 2020-Q2
2020-03-27 Ordinarie utdelning ORPHA 0.00 DKK
2020-03-26 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2020-01-25 Extra Bolagsstämma 2019
2019-08-28 Kvartalsrapport 2019-Q2
2019-03-28 Ordinarie utdelning ORPHA 0.00 DKK
2019-03-27 Årsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-08-28 Kvartalsrapport 2018-Q2
2018-04-13 Ordinarie utdelning ORPHA 0.00 DKK
2018-04-12 Årsstämma 2018
2018-03-15 Bokslutskommuniké 2017
2020-09-01 18:07:10

Orphazyme A/S
Company announcement                                                                                       

No. 47/2020                                                                                                          
Company Registration No. 32266355


Copenhagen, Denmark, September 1, 2020 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme:

1 Details of the Reporting Person / Closely Associated Person
a) Name
Sten Verland

Reason for the notification
a) Position/status
Members of the Board of Directors
b) Initial notification/Amendment
Initial notification

3
Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name
Orphazyme A/S
b) LEI code
54930025OZD2GGSQ7L42

4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code
Restricted Share Units for shares in Orphazyme A/S
ISIN DK0060910917
b) Nature of the transaction
Exercise of Restricted Share Units
c) Price(s) and volume(s)

Price (s) Volume(s)
 DKK61.18951,927

d) Aggregated information
Aggregated volume: 1,927
Aggregated price: DKK 117,912.17
Price per share (volume weighted average): DKK 61.1895
e) Date of the transaction
1 September 2020, 5 p.m. CET
f) Place of the transaction
Outside a trading venue

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code
Shares acquired by exercise of Restricted Share Units
ISIN DK0060910917
b) Nature of the transaction
Sale of shares to Sunstone Life Science Ventures Fund II K/S
c) Price(s) and volume(s)

Price (s) Volume(s)
 DKK88.301,927

d) Aggregated information
Aggregated volume: 1,927
Aggregated price: DKK 170,154.10
Price per share (volume weighted average): DKK 88.30
e) Date of the transaction
1 September 2020, 5 p.m. CET
f) Place of the transaction
Outside a trading venue


1 Details of the Reporting Person / Closely Associated Person
a) Name
Sunstone Life Science Ventures Fund II K/S

2 Reason for the notification
a) Position/status
Closely associated to Sten Verland, member of the Board of Directors
b) Initial notification/Amendment
Initial notification

3 Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name
Orphazyme A/S
b) LEI code
54930025OZD2GGSQ7L42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code
Shares acquired by exercise of Restricted Share Units
ISIN DK0060910917
b) Nature of the transaction
Purchase of shares from Sten Verland
c) Price(s) and volume(s)

Price (s) Volume(s)
 DKK88.301,927

d) Aggregated information
Aggregated volume: 1,927
Aggregated price: DKK 170,154.10
Price per share (volume weighted average): DKK 88.30
e) Date of the transaction
1 September 2020, 5 p.m. CET
f) Place of the transaction
Outside a trading venue


For additional information, please contact

Orphazyme A/S

Anders Vadsholt, CFO                                  +45 28 98 90 55


About Orphazyme A/S 
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com

Forward-looking statement 
This company announcement may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.